Hengrui Gets NMPA Approval for Fanrutingib-Camrelizumab First-Line Cervical Cancer Use
2026-07-23 12:22:16
Hengrui Medicine and its subsidiary Suzhou Shengdiya Biopharmaceutical have received notice from China's National Medical Products Administration (NMPA) approving the company's self-developed multi-target receptor tyrosine kinase (RTK) inhibitor Aibit (famitinib malate) in combination with the PD-1 inhibitor Aireka (camrelizumab injection) for first-line treatment of patients with recurrent or metastatic cervical cancer whose PD-L1 expression is positive by a fully validated test method, with a combined positive score (CPS) of at least 1, according to Jiemian News. The approval expands the regimen from second-line to first-line treatment for advanced cervical cancer.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
